<code id='6FA1590B44'></code><style id='6FA1590B44'></style>
    • <acronym id='6FA1590B44'></acronym>
      <center id='6FA1590B44'><center id='6FA1590B44'><tfoot id='6FA1590B44'></tfoot></center><abbr id='6FA1590B44'><dir id='6FA1590B44'><tfoot id='6FA1590B44'></tfoot><noframes id='6FA1590B44'>

    • <optgroup id='6FA1590B44'><strike id='6FA1590B44'><sup id='6FA1590B44'></sup></strike><code id='6FA1590B44'></code></optgroup>
        1. <b id='6FA1590B44'><label id='6FA1590B44'><select id='6FA1590B44'><dt id='6FA1590B44'><span id='6FA1590B44'></span></dt></select></label></b><u id='6FA1590B44'></u>
          <i id='6FA1590B44'><strike id='6FA1590B44'><tt id='6FA1590B44'><pre id='6FA1590B44'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:knowledge    Page View:46365
          Brain cancer
          Michelle Monje/Stanford University/NIH

          Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

          The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

          advertisement

          “We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In